APA (7th ed.) Citation

FL, G., SA, K., B, H., S, K., S, S., K, R., . . . M, E. (2026). The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management. European journal of nuclear medicine and molecular imaging, 53(5), 2994. https://doi.org/10.1007/s00259-025-07540-4

Chicago Style (17th ed.) Citation

FL, Giesel, et al. "The German Cancer Consortium (DKTK) Multi-center Prospective Phase 1/2 68Ga-PSMA-11 PET-imaging Trial in Newly-diagnosed High-risk Prostate Cancer: Safety and Diagnostic Accuracy Compared to Histopathology and Their Impact on Patient Management." European Journal of Nuclear Medicine and Molecular Imaging 53, no. 5 (2026): 2994. https://doi.org/10.1007/s00259-025-07540-4.

MLA (9th ed.) Citation

FL, Giesel, et al. "The German Cancer Consortium (DKTK) Multi-center Prospective Phase 1/2 68Ga-PSMA-11 PET-imaging Trial in Newly-diagnosed High-risk Prostate Cancer: Safety and Diagnostic Accuracy Compared to Histopathology and Their Impact on Patient Management." European Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 5, 2026, p. 2994, https://doi.org/10.1007/s00259-025-07540-4.